Ad Koster

Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma

Steven Wang, Parisa Mapar, Norbert Moldován, Ymke van der Pol et autres

Curative-intent immunochemotherapy fails in ~30% of patients with large B-cell lymphoma (LBCL), yet no validated molecular tool enables early identification of high-risk individuals to guide treatment intensification. Using shallow whole genome sequencing (sWGS) of plasma cell-free DNA from 190 LBCL patients, we …

nl, fi, gb (code pays fourni par la source)

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

Steven Wang, Marcel Nijland, Leonie Strobbe, Margriet Oosterveld et autres

PURPOSE End-of-treatment (EOT) response evaluation by positron emission tomography (PET) remains suboptimal in patients with large B-cell lymphoma (LBCL), because of its limited positive predictive value (PPV). Circulating tumor DNA (ctDNA)—based measurable residual disease (MRD) detection offers a minimally invasive approach and …

nl, us (code pays fourni par la source)

Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial.

Steven Wang, Marcel Nijland, Leonie Strobbe, Margreet Oosterveld et autres

7000 Background: The prognostic utility of circulating tumor DNA measurable residual disease (ctDNA-MRD) detection at end of treatment (EOT) using phased variant (PV) enrichment and detection sequencing (PhasED-Seq) has been demonstrated in patients with diffuse large B-cell lymphoma (DLBCL) receiving first-line (1L) …

nl, us (code pays fourni par la source)

Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Steven Wang, Parisa Mapar, Ymke van der Pol, Norbert Moldován et autres

Purpose: Diffuse large B-cell lymphoma (DLBCL) patients need an accurate and early risk stratification strategy, as prompt therapy escalation may improve outcomes. Cell-free DNA (cfDNA) is an emerging liquid biopsy biomarker that has demonstrated clinical utility in guiding cancer treatment. Patients and …

nl, be, gb (code pays fourni par la source)

Quality of Life Gains in Frail and Intermediate-Fit Patients with Multiple Myeloma: Findings from the Prospective Hovon123 Clinical Trial

Maarten R. Seefat, Claudia A.M. Stege, Birgit Ilja Lissenberg-Witte, Mark‐David Levin et autres

nl, Gabon, us, no (code pays fourni par la source)

Red blood cells from patients with sitosterolemia exhibit impaired membrane lipid composition and distribution and decreased deformability

Anne‐Sophie Cloos, Minke A.E. Rab, Patrick Van Deŕ Smissen, Brigitte A. van Oirschot et autres

Sitosterolemia is a metabolic disorder leading to excessive accumulation of phytosterols. Hemolytic stomatocytosis and macrothrombocytopenia are part of the clinical picture. However, the impact of phytosterols on red blood cell (RBC) deformability, membrane lipid composition and distribution and the efficiency of the …

be, nl (code pays fourni par la source)

Clinical impact of assessing thrombus age using magnetic resonance venography prior to catheter-directed thrombolysis

Carsten W. K. P. Arnoldussen, Pascale Notten, Rutger Brans, Dammis Vroegindeweij et autres

OBJECTIVES: Magnetic resonance venography (MRV) is underutilized in the evaluation of thrombus properties prior to endovascular treatment but may improve procedural outcomes. We therefore investigated the clinical impact of using a dedicated MRV scoring system to assess thrombus characteristics prior to endovascular …

nl, de (code pays fourni par la source)

Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

Sander Kuiper, Cees van Nieuwkoop, Robert Jan Hassing, Suzan P. van Mens et autres

BACKGROUND: We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women. METHODS: This was a double-blind, randomized, controlled trial in 15 Dutch hospitals. Adult women who …

nl (code pays fourni par la source)

Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled Trial

Simone Oerlemans, Lindy P. J. Arts, Jacobien Marije Kieffer, Judith B. Prins et autres

BACKGROUND: There has been a cultural shift toward patient engagement in health, with a growing demand from patients to access their results. OBJECTIVE: The Lymphoma Intervention (LIVE) trial is conducted to examine the impact of return of individual patient-reported outcome (PRO) results …

nl (code pays fourni par la source)

CAVA (Ultrasound‐Accelerated Catheter‐Directed Thrombolysis on Preventing Post‐Thrombotic Syndrome) Trial: Long‐Term Follow‐Up Results

Pascale Notten, André A. E. A. de Smet, Lidwine Winnifred Tick, Marlène H. W. van de Poel et autres

Background The CAVA (Ultrasound‐Accelerated Catheter‐Directed Thrombolysis Versus Anticoagulation for the Prevention of Post‐Thrombotic Syndrome) trial did not show a reduction of post‐thrombotic syndrome (PTS) after additional ultrasound‐accelerated catheter‐directed thrombolysis in patients with acute iliofemoral deep vein thrombosis at 1‐year follow‐up. This prespecified …

nl (code pays fourni par la source)

Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Claudia A.M. Stege, Kazem Nasserinejad, Saskia K. Klein, Gert-Jan Timmers et autres

nl, us (code pays fourni par la source)

Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled Trial (Preprint)

Simone Oerlemans, Lindy P. J. Arts, Jacobien Marije Kieffer, Judith B. Prins et autres

BACKGROUND There has been a cultural shift toward patient engagement in health, with a growing demand from patients to access their results. OBJECTIVE The Lymphoma Intervention (LIVE) trial is conducted to examine the impact of return of individual patient-reported outcome (PRO) results …

nl (code pays fourni par la source)